Medication info

Posip Duo Sustained Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Donghwa Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped sustained-release film-coated tablet with convex sides
Packaging
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202300148 · Approved 2023.01.06

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce the gastrointestinal adverse reactions associated with metformin. For patients receiving treatment with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the same dose of metformin the patient was taking or an appropriately equivalent therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because such a change may lead to alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this drug may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this drug must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is likely to decline in older adults, this drug should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Ingredients

Manufacturer
Donghwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with poor blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medicine helps to improve blood sugar control in adult patients with type 2 diabetes by using dapagliflozin and metformin together. It can be more effective in managing blood sugar when combined with dietary and exercise therapy. In particular, for patients whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors, the cardiovascular event prevention effect of dapagliflozin should also be considered. This medicine is used for the blood sugar control and cardiovascular health management of patients with type 2 diabetes.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce the gastrointestinal adverse reactions associated with metformin. For patients receiving treatment with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the same dose of metformin the patient was taking or an appropriately equivalent therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because such a change may lead to alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this drug may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this drug must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is likely to decline in older adults, this drug should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient subsection).

Precautions

This medicine is used for blood sugar control and should not be administered to patients with poor kidney function or severe renal impairment. Patients should consult a doctor immediately if dehydration, serious infections, or cardiovascular problems occur while taking this medicine, and drug administration may need to be temporarily discontinued in these situations. Pregnant or nursing women should not take this medicine, and those receiving treatment should quickly receive treatment if symptoms of genital infections or urinary tract infections occur, as the risk of such infections may increase. This medicine may cause hypoglycemia; therefore, when used with insulin or sulfonylureas, careful monitoring of blood sugar changes is required and dose adjustments may be necessary. Patients should undergo regular kidney function tests before and during treatment, and if kidney function deteriorates, the use of this medicine should be discontinued. Additionally, this medicine may cause decreased fluid volume or low blood pressure, so particularly elderly patients or those taking diuretics should closely monitor their blood pressure and fluid status. If surgery or tests using iodinated contrast agents are planned while taking this medicine, it should be discontinued at least 48 hours prior and restarted only after confirming kidney function. This medicine may reduce vitamin B12 levels, so it is advisable to regularly check vitamin B12 concentrations during prolonged use. Excessive alcohol consumption may increase the risk of side effects of this medicine, so caution is required. In the event of overdose, seek appropriate medical attention immediately, and this medicine has not been established for safety and efficacy in children. Finally, this medicine should be kept out of the reach of children and stored in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbar pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • reduced renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated serum urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialoadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland tumor
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent air or moisture ingress, at a temperature between 1 to 30 degrees Celsius. This storage condition will maintain the medicine's effectiveness and ensure safe usage.

Appearance and packaging

Appearance

Yellow, oval-shaped sustained-release film-coated tablet with convex sides

Package unit

30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.